This series explores the development and clinical utility of CAR T-cell therapy in treating patients with mantle cell lymphoma.
EP. 1: EP. 1: Exploring CAR T-Cell Therapy in Patients with Mantle Cell Lymphoma
August 2nd 2022In an interview with Targeted OncologyTM, Leslie, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.